Article thumbnail

Prognostic Impacts of Angiopoietins in NSCLC Tumor Cells and Stroma: VEGF-A Impact Is Strongly Associated with Ang-2

By Sigve Andersen, Tom Donnem, Khalid Al-Shibli, Samer Al-Saad, Helge Stenvold, Lill-Tove Busund and Roy M. Bremnes
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2008). Angiogenic switch of angiopietins-Tie2 system and its prognostic value in bladder cancer.
  2. (2008). Angiopoietin-1 and -2 expression in recurrent squamous cell carcinoma of the oral cavity.
  3. (2009). Angiopoietin-1 overexpression modulates vascular endothelium to facilitate tumor cell dissemination and metastasis establishment.
  4. (2009). Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade.
  5. (2010). Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis.
  6. (2010). Angiopoietin1/Tie2 receptor signaling in vascular quiescence and angiogenesis.
  7. (2006). Angiopoietin4 inhibits angiogenesis and reduces interstitial fluid pressure.
  8. (2008). Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts.
  9. (2004). Biological characterization of angiopoietin-3 and angiopoietin-4.
  10. (2009). Cancer statistics,
  11. (2009). Cancer: Inflaming metastasis.
  12. (2003). CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are Angiopoietins and Prognosis
  13. (2009). Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system.
  14. (1995). Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation.
  15. (2006). Expression and prognostic significance of angiopoietin in colorectal carcinoma.
  16. (2002). Expression of angiopoietins and its clinical significance in non-small cell lung cancer.
  17. (2010). How do angiopoietins Tie in with vascular endothelial growth factors?
  18. (2004). in gastric carcinoma; immunohistochemical analyses and correlation with clinicopathological factors.
  19. (2007). in gastrointestinal stromal tumor, leiomyoma and schwannoma.
  20. (2007). Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer.
  21. (2005). Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer.
  22. (2004). Overexpression of Ang-2 mRNA in non-small cell lung cancer: association with angiogenesis and poor prognosis.
  23. (2008). Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer.
  24. (2008). Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer.
  25. (2007). Prognostic significance of vessel architecture and vascular stability in nonsmall cell lung cancer.
  26. (1999). Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.
  27. (2010). Targeting the ANGPT-TIE2 pathway in malignancy.
  28. (2009). The 7th Edition of TNM in Lung Cancer: what now?
  29. (2009). The angiopoietin 1/angiopoietin 2 balance as a prognostic marker in primary glioblastoma multiforme.
  30. (2000). The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas.
  31. (2000). The hallmarks of cancer.
  32. (2008). The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer.
  33. (1995). The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells.
  34. (1999). World Health Organization